This ongoing skeletal remodeling imbalance may be further mediated by wingless/integrated (Wnt) pathway inhibitors such as sclerostin and Dickkopf-1 (DKK1), which are upregulated in CKD and contribute to both bone fragility and vascular calcification (47). Here, SOST is linked to chronic kidney disease.